跳至主要内容
临床试验/NCT05486832
NCT05486832
招募中
不适用

"TARGET Study": Safety and Performance of the Cardiovalve TR Replacement System for Tricuspid Regurgitation

Cardiovalve Ltd.13 个研究点 分布在 1 个国家目标入组 100 人2022年12月9日

概览

阶段
不适用
干预措施
Cardiovalve TR valve replacement System
疾病 / 适应症
Tricuspid Regurgitation
发起方
Cardiovalve Ltd.
入组人数
100
试验地点
13
主要终点
Freedom from device or procedure-related adverse events
状态
招募中
最后更新
3个月前

概览

简要总结

The objective of this study is to evaluate the safety and performance of Cardiovalve TR system

详细描述

The study is a multi-center, prospective, single arm study designed to evaluate the safety and performance of the Cardiovalve Tricuspid Valve Replacement System

注册库
clinicaltrials.gov
开始日期
2022年12月9日
结束日期
2033年12月15日
最后更新
3个月前
研究类型
Interventional
研究设计
Single Group
性别
All

研究者

责任方
Sponsor

入排标准

入选标准

  • Functional TR ≥3+
  • Symptomatic, NYHA Class II-IVa
  • Patient approved by the Subject Screening Committee

排除标准

  • Cardiac anatomy deemed not suitable for the Cardiovalve TR system
  • Hemodynamic instability
  • Severe right ventricular failure
  • Refractory heart failure requiring advanced intervention

研究组 & 干预措施

Cardiovalve TR replacement Group

Cardiovalve TR valve replacement System

干预措施: Cardiovalve TR valve replacement System

结局指标

主要结局

Freedom from device or procedure-related adverse events

时间窗: 30 days

Freedom from device or procedure-related adverse events

Reduction in TR grade

时间窗: 30 days

Reduction in TR in comparison to baseline

次要结局

  • Six minute walk test(30 days, 6 months, 12 months, annual for five years)
  • KCCQ(30 days, 6 months, 12 months, annual for five years)

研究点 (13)

Loading locations...

相似试验